84,034 Exponent, Inc. $EXPO Shares Sold by Royce & Associates LP

Royce & Associates LP trimmed its position in shares of Exponent, Inc. (NASDAQ:EXPO – Free Report) by 6.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,239,063 shares of the business services provider’s stock after selling 84,034 shares during the quarter. Exponent makes up about 0.7% of Royce & Associates LP’s investment portfolio, making the stock its 9th largest holding. Royce & Associates LP’s holdings in Exponent were worth $81,060,000 at the end of the most recent reporting period.

Several other large investors have also made changes to their positions in EXPO. Gibbs Wealth Management increased its holdings in Exponent by 3.1% in the third quarter. Gibbs Wealth Management now owns 4,759 shares of the business services provider’s stock worth $311,000 after buying an additional 142 shares during the last quarter. Covestor Ltd raised its position in Exponent by 10.3% during the third quarter. Covestor Ltd now owns 2,050 shares of the business services provider’s stock valued at $134,000 after acquiring an additional 192 shares in the last quarter. Bessemer Group Inc. lifted its stake in Exponent by 37.1% in the first quarter. Bessemer Group Inc. now owns 717 shares of the business services provider’s stock valued at $47,000 after acquiring an additional 194 shares during the last quarter. State of Michigan Retirement System lifted its stake in Exponent by 1.7% in the first quarter. State of Michigan Retirement System now owns 12,000 shares of the business services provider’s stock valued at $783,000 after acquiring an additional 200 shares during the last quarter. Finally, GAMMA Investing LLC lifted its stake in Exponent by 9.4% in the second quarter. GAMMA Investing LLC now owns 2,509 shares of the business services provider’s stock valued at $147,000 after acquiring an additional 216 shares during the last quarter. Institutional investors own 92.37% of the company’s stock.

Analysts Set New Price Targets

EXPO has been the subject of a number of recent research reports. Zacks Research upgraded shares of Exponent from a “hold” rating to a “strong-buy” rating in a report on Monday, November 2nd. UBS Group increased their target price on shares of Exponent from $72.00 to $82.00 and gave the stock a “neutral” rating in a research report on Friday, October 30th. Weiss Ratings upgraded Exponent from a “hold (c)” rating to a “hold (c+)” rating in a report on Monday, November 9th. Finally, JPMorgan Chase & Co. boosted their price target on Exponent from $90.00 to $100.00 and gave the stock an “overweight” rating in a research report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Exponent has an average rating of “Moderate Buy” and an average price target of $91.00.

View Our Latest Report on Exponent

Insider Buying and Selling at Exponent

In related news, VP Richard Reiss sold 1,280 shares of Exponent stock in a transaction on Tuesday, November 3rd. The shares were sold at an average price of $86.44, for a total value of $110,643.20. Following the transaction, the vice president owned 1,008 shares in the company, valued at $87,131.52. This trade represents a 55.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Catherine Corrigan sold 1,707 shares of Exponent stock in a transaction on Monday, August 17th. The stock was sold at an average price of $66.28, for a total transaction of $113,139.96. Following the completion of the transaction, the chief executive officer owned 129,108 shares in the company, valued at $8,557,278.24. This trade represents a 1.30% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.70% of the stock is currently owned by corporate insiders.

Exponent Price Performance

EXPO traded up $1.09 on Friday, hitting $87.31. The company had a trading volume of 273,050 shares, compared to its average volume of 534,213. The stock has a market cap of $4.15 billion, a price-to-earnings ratio of 37.63 and a beta of 0.66. The company’s fifty day moving average price is $73.30 and its 200 day moving average price is $67.23. Exponent, Inc. has a 1-year low of $51.91 and a 1-year high of $90.51.

Exponent (NASDAQ:EXPO – Get Free Report) last announced its quarterly earnings results on Thursday, October 29th. The business services provider reported $0.64 EPS for the quarter, beating the consensus estimate of $0.60 by $0.04. Exponent had a return on equity of 34.61% and a net margin of 17.40%. The company had revenue of $173.73 million for the quarter, compared to the consensus estimate of $149.64 million. During the same quarter last year, the company posted $0.55 earnings per share. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. On average, sell-side analysts forecast that Exponent, Inc. will post 2.36 EPS for the current year.

Exponent Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 18th. Investors of record on Friday, December 4th will be issued a dividend of $0.31 per share. This represents a $1.24 annualized dividend and a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, December 4th. Exponent’s dividend payout ratio is currently 53.45%.

Exponent Company Profile

(Free Report)

Exponent, Inc. is a multidisciplinary engineering and scientific consulting firm that helps clients investigate complex technical issues and manage risk. Its consultants analyze incidents such as product failures and accidents, assess potential hazards, and provide expert advice on engineering, scientific, and regulatory matters. The company’s services span fields including engineering, materials science, environmental science, health, and data analytics. Clients use Exponent’s expertise for product development and testing, litigation support, regulatory compliance, and risk assessment across a range of industries.

Further Reading

Want to see what other hedge funds are holding EXPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exponent, Inc. (NASDAQ:EXPO – Free Report).

Institutional Ownership by Quarter for Exponent (NASDAQ:EXPO)

Receive News & Ratings for Exponent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exponent and related companies with MarketBeat.com's FREE daily email newsletter.